Hyperphosphatemia Drugs Market to Expand at a steady Growth RatePosted by andrew on October 14th, 2019 Hyperphosphatemia is a condition which results in an elevated level of phosphate in the blood. This may occur due to excessive phosphate intake, phosphate shift from intracellular to extracellular space, and decreased phosphate excretion. High phosphate levels in blood can be avoided by use of phosphate binders and dietary constraint of phosphates. Major factors that drive the Hyperphosphatemia Drugs Market growth are growth in prevalence of chronic diseases and growth in geriatric population. However, stringent regulations by the drug-governing bodies such as FDA and rise in side effects of hyperphosphatemia drugs may impede the market growth. Moreover, high potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-toc-and-sample/4408
Comprehensive competitive analysis and profiles of major players, such as Amag Pharmaceuticals, Johnson and Johnson, Keryx Biopharmaceuticals, DSM Biotech Pharmacal, Sun Pharm Inc., Zeria Pharmaceutical, Bruno Pharmaceutical Spa, Fermenta Biotech Ltd, Pfizer Inc. and Roche Diagnostics Corporation are also provided in this report. The global hyperphosphatemia drugs market is segmented based on product, dosage form, and region. Based on product, it is divided into calcium-based, aluminum-based, magnesium-based, and iron-based phosphate binders. Based on dosage form, it is classified into tablets, syrups, and capsules. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Key Benefits
Like it? Share it!More by this author |